Last reviewed · How we verify

Eli Lilly — Portfolio Competitive Intelligence Brief

Eli Lilly (LLY) pipeline: 43 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

LLY (NYSE) 43 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ebglyss LEBRIKIZUMAB marketed Interleukin-13 Antagonist [EPC] Immunology 2025-01-01
Inluriyo IMLUNESTRANT marketed Estrogen Receptor Antagonist [EPC] Oncology 2025-01-01
Omvoh MIRIKIZUMAB marketed Interleukin-23 Antagonist [EPC] Interleukin-23 subunit alpha Immunology 2023-01-01
Mounjaro TIRZEPATIDE marketed Dual GIP/GLP-1 receptor agonist GIP receptor and GLP-1 receptor Metabolic 2022-01-01
Retevmo SELPERCATINIB marketed Kinase Inhibitor [EPC] Proto-oncogene tyrosine-protein kinase receptor Ret Oncology 2020-01-01
Ly-Cov016 ETESEVIMAB marketed Infectious Disease 2020-01-01
Reyvow LASMIDITAN marketed 5-hydroxytryptamine receptor 1F Neuroscience 2019-01-01
Olumiant baricitinib marketed Janus Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK2 Immunology 2018-01-01
Emgality GALCANEZUMAB marketed Calcitonin gene-related peptide 1 Neuroscience 2018-01-01
Verzenio abemaciclib marketed Kinase inhibitor Cyclin-dependent kinases 4 and 6 (CDK4/CDK6) Oncology 2017-01-01
Lartruvo OLARATUMAB marketed Platelet-derived Growth Factor Receptor alpha Antagonist Platelet-derived growth factor receptor alpha Oncology 2016-01-01
Taltz ixekizumab marketed Interleukin-17A antagonist Interleukin 17A (IL-17A) cytokine Immunology 2016-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

Competitive overlap (companies sharing drug classes)

  1. · 7 shared drug classes
  2. Pfizer · 4 shared drug classes
  3. AbbVie · 3 shared drug classes
  4. Sanofi · 3 shared drug classes
  5. AstraZeneca · 3 shared drug classes
  6. Johnson & Johnson · 2 shared drug classes
  7. Boehringer Ingelheim · 2 shared drug classes
  8. Novo Nordisk · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Eli Lilly:

Cite this brief

Drug Landscape (2026). Eli Lilly — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eli-lilly. Accessed 2026-05-13.

Related